

1. Capretti L., Bonora E., Coscelli C., Butturini U. Combined sulphonylurea-biguanide therapy for NIDDM. Metabolic effects of glibenclamide and metformin or phenformin in newly diagnosed obese patients. *Curr. Med. Res. Opinion* 7: 677-683, 1982.
2. Fallucca F, Barbetti F, Maldonato A, Spallone V, Giangrande L, Gambardella S. Effects of somatostatin on established induced ketosis. *Horm Metabol Research* 14: 512-515, 1982.
3. Vigneri R, Pezzino V, Wong KY, Goldfine ID. Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to its receptors in target cells. *J Clin Endocrinol Metab.* 54:95-100, 1982.
4. Pezzino V, Trischitta V, Purrello F, Vigneri R. Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells. *Diabetologia* 23:131-135, 1982.
5. Trischitta V, Gullo D, Pezzino V, Vigneri R. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients. *J Clin Endocrinol Metab.* 57:713-718, 1983.
6. Goldfine ID, Iwamoto Y, Pezzino V, Trischitta V, Purrello F, Vigneri R. Effects of biguanides and sulfonylureas on insulin receptors in cultured cells. *Diabetes Care* 7 (Suppl 1):54-58., 1984.
7. Vigneri R, Gullo D, Pezzino V. Metformin and insulin receptors. *Diabetes Care* 7 (Suppl 1):113-117, 1984.
8. Bonora E., Cigolini M., Bosello O., Zancanaro C., Capretti L., Zavaroni I., Coscelli C., Butturini U. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in nondiabetic subjects. *Curr. Med. Res. Opinion* 9: 47-51, 1984.
9. Coscelli C., Palmari V., Saccardi F., Alpi O., Bonora E. Evidence that metformin addition to insulin induces an amelioration of glycemic profile in type I (insulin-dependent) diabetes mellitus. *Curr. Therap. Res.* 35: 1058-1064, 1984.
10. Sinagra D Optimum therapy of insulin-dependent diabetes mellitus. *Recenti Prog Med.* Sep;75(9):823-32, 1984.
11. Ferrara L, Capaldo B, Rivellese AA, Genovese S, Iovine C, Russo L, Mancini M. Effects of β -receptor blockade on carbohydrate metabolism. *JOURNAL OF HYPERTENSION*, vol. 3 (suppl. 3), p. 199-201, 1985.
12. Parillo M., Giacco R., Riccardi G., Pacioni D., Rivelles A Different glycaemic responses to pasta, bread, and potatoes in diabetic patients *Diabetic Medicine* 2:374, 1985.
13. Rivellese A., Parillo M., Iovine C., Giacco A., De Marco F, Perrotti N., Riccardi G.,

- Mancini M. A fibre rich diet for the treatment of diabetic patients with chronic renal failure. Diabetes Care 8, 1985.
- 14.** Pozzilli P, Ghirlanda G, Manna R, Alfano G, Greco AV, Andreani D. White cells transfusion in recent onset type 1 diabetes. Diabetes Res. 3(5):273-6, 1986.
- 15.** Ferrara L, Capaldo B, Rivellesse A, Genovese S, Iovine C, Mastranzo P, Cirillo F, Mancini M. Adrenergic system and carbohydrate metabolism. Effects of beta receptor blockade on insulin secretion and peripheral insulin sensitivity in normoglycemic patients. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 33, p. 273-277, 1987.
- 16.** Bonora E., Pisani F., Micciolo R., Cognati A., Muggeo M. Effect of glipizide on insulin secretion and insulin metabolism in obese type 2 diabetic patients. Diabetes Care 10: 687-691, 1987.
- 17.** Pozzilli P, Visalli N, Cavallo MG, Beales P, Negri M, Ghirlanda G, Papa V, Andreani D. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin. Diabetes Res. Oct;6(2):51-6, 1987.
- 18.** Maldonato A, Iavicoli M, Fallucca F. When to start a NIDDM patient on insulin: which insulin programme could be recommended? Diabetes Res Clin Pract 4: 29-34, 1988.
- 19.** Purrello F, Gullo D, Buscema M, Pezzino V, Vigneri R, Goldfine ID. Metformin enhances certain insulin actions in cultured rat hepatoma cells. Diabetologia; 31:385-389, 1988.
- 20.** Cignarelli M, Cospito MR, Rosco M, Garruti G, De Pergola G, Giorgino R. Responses to chickling vetch and bread meals in normal and type 2 non-insulin-dependent diabetic subjects. Diab. Med. 5: 501-502, 1988.
- 21.** Cignarelli M, De Pergola G, Paternostro A, Garruti G, Cospito MR, Nardelli GM, Giorgino R. Plasma glucose, free fatty acids and insulin response to single and mixed chickling vetch (*lathyrus sativus*) meal in type 2 non-insulin-dependent diabetic subjects. Diab. Nutr. Metab.; 1: 187-191, 1988.
- 22.** Pezzarossa A., Taddei F., Cimicchi M.C., Rossini E., Contini S., Bonora E., Gnudi A., Uggeri E. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 11: 52-58, 1988.
- 23.** Pozzilli P. Immunotherapy in type 1 diabetes. Diabet Med. 5(8):734-8, 1988.
- 24.** Bonora E., Muggeo M. Further considerations regarding insulin secretion and metabolism after glipizide treatment. Diabetes Care 11: 690-692, 1988.
- 25.** Parillo M., Pacioni D., Iovine C, Contaldo F., Isernia C, Demarco F., Perrotti N., Rivellesse A. Metabolic effects of a high CHO-high fibre diet for the treatment of diabetic patients with

- chronic kidney failure. Am J Clin Nutr 48:255-9, 1988.
26. Parillo M., Coulston A., Hollenbeck C., Reaven G: Effect of a low fat diet on carbohydrate metabolism in patients with hypertension. Hypertension, 244-248, 1988.
27. Parillo M, Giacco R, Rivellese A, Giacco A, Iovine C, Riccardi G. Acute effects on pancreatic hormones and blood lipids of bread and spaghetti consumed within a meal. Diab Nutr Metab 1:133, 1988.
28. Perriello G, Torlone E, Di Santo S, Fanelli C, De Feo P, Santeusanio F, Brunetti P, Bolli GB. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 31(11):811-5, 1988.
29. Sinagra D, Randazzo C. Alternative systems of insulin administration. G Clin Med. 70(8-9):529-34, 1989.
30. Trischitta V, Italia S, Borzì V, Tribolato A, Mazzarino S, Squatrito S, Vigneri R. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide. Diabetes Care; 12: 582-585, 1989.
31. Pozzilli P, Kolb H. Immunotherapy in type 1 diabetes: present status. Immunol Today. 10(10):321-2, 1989.
32. Kolb H, Bach JF, Eisenbarth GS, Harrison LC, Maclaren NK, Pozzilli P, Skyler JS, Stiller CR. Criteria for immune trials in type I diabetes. Lancet. 16;2(8664):686, 1989.
33. Bach JF, Dupré J, Eisenbarth GS, Harrison LC, Maclaren NK, Nerup J, Pozzilli P. Immunotherapy in pre-type 1 diabetes mellitus. Diabetologia. 33(12):741, 1990.
34. Sinagra D. Semifasting and type II diabetes mellitus. Recenti Prog Med. Feb;81(2):79-82, 1990.
35. Di Cianni G, Benzi L, Ciccarone AM, Cecchetti P, Giannarelli R, Penno G, Navalesi R. Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations. Clin Ter. 134: 187-91, 1990.
36. Mancini G, Parillo M: Lipid Intake and Atherosclerosis. Ann Nutr Metab 35:103-108, 1991.
37. Vigneri R., Trischitta V., Italia S, Mazzarino S., Rabuazzo M.A., Squatrito . Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab 17: 232-234, 1991.
38. Parillo M, Rivellese A. A., Ciardullo A. V, Capaldo B., Giacco A, Genovese S., Riccardi G A high monounsaturated-fat/low-CHO diet improves peripheral insulin sensitivity in non insulin dependent diabetic patients. Metabolism 41: 1373-1378, 1992.

- 39.** Trischitta V., Italia S., Mazzarino S., Buscema M, Rabuazzo A.M., Sangiorgio L., Squatrito S, Vigneri R. Comparison of combined therapies in treatment of secondary failure to glyburide. *Diabetes Care* 15: 539-542, 1992.
- 40.** Parillo M, Mura A., Iovine C., Rivellesse A., Iavicoli M, Riccardi G. Prevention of early morning hyperglycemia in insulin-dependent diabetic patients with long acting Zn-insulin. *Diabetes Care* 15, 12: 173-177, 1992.
- 41.** Bonora E., Moghetti P., Querena M., Zenere M., Cacciatori, V., Tosi F., Travia D., Zoppini G., Muggeo M. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. *J. Endocrinol. Invest.* 14: 1-11, 1992.
- 42.** Coscelli C., Calabrese G., Fedele D., Pisu E., Calderini C., Bistoni S., Lapolla A., Mauri M.G., Rossi A., Zappella A. Use of premixed insulin among the elderly. Reduction of errors in patients preparation of mixture.. *Diabetes Care* 15 (11), 1628-1630, 1992.
- 43.** Pozzilli P, Signore A, Andreani D. What future for therapeutic prevention of type 1 (insulin-dependent) diabetes mellitus? *Diabetologia*. 35(11):1093-5, 1992.
- 44.** Visalli N, Pozzilli P, Boccuni ML, Suppa MA, Messina R, Buzzetti R, Andreani D. Immunointervention in insulin dependent diabetes: implications for the epidemiology of the disease. *Ann Ig.* 4(3):159-63, 1992.
- 45.** Krug J, Lampeter EF, Williams AJ, Procaccini E, Cartledge C, Signore A, Beales PE, Pozzilli P. Immunotherapy with ciamexon in the non obese diabetic (NOD) mouse. *Horm Metab Res.* 24(1):1-4, 1992.
- 46.** Leslie RD, Carotenuto P, Pozzilli P. New developments in non-specific and semi-specific immunosuppression in type I diabetes. *Diabetes Metab Rev.* 9(4):257-67, 1993.
- 47.** Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. *Diabetes Care*. 16(10):1387-90, 1993.
- 48.** Scavini M, Pincelli AI, Cruciani C, Giberti B, Orsi E, Galimberti G, Petrella G, Cristallo M, Pozza G, Micossi P. Influence of meal ingestion on insulin profiles following intraperitoneal delivery. *Metabolism*. 42:1013-1016, 1993.
- 49.** Giugliano D, De Rosa N, Marfella R, Di Maro G, Cacciapuoti F, Quatraro A, Acampora R, D'Onofrio F. Comparison of nifedipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. *American Journal of Hypertension*. 6(11 Pt 1):927-32, 1993.
- 50.** Pozzilli P, Maclaren NK. Immunotherapy at clinical diagnosis of insulin-dependent diabetes: an approach still worth considering. *Trends Endocrinol Metab.* 4(3):101-5, 1993.

- 51.** Muir A, Schatz DA, Pozzilli P, MacLaren NK. Intervention therapies for insulin-dependent diabetes. *Autoimmunity*. 16(4):301-10, 1993.
- 52.** Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L, et al. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study. *Diabetes Care*. 17(8):897-900, 1994.
- 53.** Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L, et al. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. *Diabet Med*. 11(1):98-104, 1994.
- 54.** Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Panpanelli S, Brunetti P, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. *Diabetologia*. 37(7):713-20, 1994.
- 55.** Panpanelli S, Torlone E, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. *Diabetes Care*. 18(11):1452-9, 1995.
- 56.** Parillo M., Riccardi G Dietary carbohydrate and glucose metabolism in diabetic patients. *Diabete e Metabolisme* 21:391-401,1995.
- 57.** Pozzilli P, Visalli N, Buzzetti R, Baroni MG, Boccuni ML, Fioriti E, Signore A, Mesturino C, Valente L, Cavallo MG, et al. Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. *Diabete Metab*. 21(1):47-9, 1995.
- 58.** Letizia C, d'Ambrosio C, De Cioccis A, Scavo D, Pozzilli P. Serum angiotensin-converting enzyme levels in patients with recent-onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy. IMDIAB Study Group. *Int J Clin Pharmacol Res*. 15(5-6):209-13, 1995.
- 59.** Trevisan R, Tiengo A., Fedele D., Lapolla A and the North-East Italy Microalbuminuria Study Group. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non insulin dependent diabetic patients. *Am. J. Hypertens*. 8: 876-883, 1995.
- 60.** Fallucca F, Sciullo E, Maldonato A. Combined therapy with insulin and sulfonylureas for the treatment of new-onset insulin-dependent diabetes mellitus. *Horm Metab Res* 28: 86-88, 1996.

- 61.** Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R, Giugliano D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. *Diabetes Care*. 19(9):934-9, 1996.
- 62.** Cusi K., Consoli A., De Fronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. *J Clin Endocr. Metab.*, 81:4012-4019,1996.
- 63.** Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. *Diabetes Care*. 19(12):1357-63, 1996.
- 64.** Signore A, Fiore V, Chianelli M, Procaccini E, Barone R, Ronga G, Negri M, Pozzilli P. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes. *Diabetes Res Clin Pract*. 33(2):83-7, 1996.
- 65.** Torlone E, Panpanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. *Diabetes Care*. 19(9):945-52, 1996.
- 66.** Pozzilli P, Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, Lucentini L, Matteoli MC, Crinò A, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Suppa M, Sulli N, De Mattia G, Faldereta MR. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). *Eur J Endocrinol*. 137(3):234-9, 1997.
- 67.** Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. *Ann Intern Med*. 126(12):955-9, 1997.
- 68.** Pozzilli P. BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group. *Lancet*. 24;349(9064):1520-1, 1997.
- 69.** De Toni S, Piva E, Lapolla A, Fontana G, Fedele D, Plebani M. Respiratory burst of neutrophils in diabetic patients with periodontal disease. *Ann N Y Acad Sci*. 15;832:363-7, 1997.
- 70.** Giacco R, Brighenti F, Parillo M, Rivellese A, Riccardi G. Potato Dumplings elicit a low plasma glucose response in NIDDM patients. *Diabetes Care* 20,460, 1997.
- 71.** Trischitta V., Italia S., Raimondo M., Guardabasso V, Licciardello C., Runello F, Mazzarino S., Sangiorgi L., Anello M., Vigneri R. Efficacy of combined treatments in

- NIDDM patients with secondary failure to sulphonilureas. Is it predictable? *J Endocrinol Invest* 21;744-747, 1998.
72. Giacco R., Brighenti F., Parillo M et al.. Are the beneficial metabolic effects of fibre enriched foods preserved when consumed within a composite meal? *Diabetes Nutrition & Metabolism* 130-137, 1998.
73. Sinagra D, Scarpitta AM, Amato M Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. *Eur Rev Med Pharmacol Sci.* 2(5-6):175-9, 1998.
74. Torlone E. Recombinant human insulin analogues: recommendations for optimal use. *BioDrugs.* 9(5):363-74, 1998.
75. . Fontana G., Lapolla A., Sanzari M., Piva E., Mussap M., De S Toni,. Plebani M, Fusetti F., Fedele D An immunological evaluation of type 2 diabetic patients with periodontal disease. *Journal Diabetes and its Complications* 13: 13-23, 1999.
76. Riccardi G, Giacco R., Parillo M et al Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled,double-bind,multicentre study. *Diabetic Medicine* 16,228-32, 1999.
77. Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Lucentini L, Matteoli MC, Crinò A, Corbi S, Spera S, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Sulli N, Cervoni M, De Mattia G, Fal detta MR, Boscherini B, Pozzilli P, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). *Diabetes Metab Res Rev.* 15(3):181-5, 1999.
78. Beales PE, Pozzilli P. Caution is required with interferon alpha as a potential treatment for type I diabetes. *Diabetologia.* 42(3):385, 1999.
79. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. *Diabetes Care.* 22(5):795-800, 1999.
80. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. *Diabetes Care.* 22(3):468-77, 1999.
81. Pozzilli, P., Pitocco, D., Visalli, N., Cavallo, M.G., Buzzetti, R., Crinò, A., Spera, S., Giordano C., Sbriglia M, Sarugeri E, Ghirlanda, G No effect of oral insulin on residual beta-

- cell function in recent-onset Type I diabetes (the IMDIAB VII). *Diabetologia* 43 (8) , pp. 1000-1004, 2000.
82. Gentili P, Maldonato A, Bloise D, Burla F, Coronel G, Di Paolantonio T. Personality variables and compliance with insulin therapy in type 2 diabetic subjects. *Diabetes Nutr Metab* 13: 1-6, 2000.
83. Giacco R., Parillo M, Rivellese AA,, Lasorella G, Giacco A., D'Episcopo L., Riccardi G Long term dietary treatment with increased amounts of fiber rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. *Diabetes Care* 23,1461-66, 2000.
84. Giacco R., Brighenti F, Parillo M., Capuano M, Ciardullo AV, Rivieccio A, Rivellese AA, Riccardi G. Characteristics of some wheat-based foods of the Italian diet in relation to their influence on post prandial glucose metabolism in patients with type 2 diabetes. *British Journal of Nutrition* 85,33-40, 2001.
85. Gentili P, Maldonato A, Grieco R, Santini A. Influence of patients' representations and beliefs about diabetes and its treatment on their adherence to therapy. *Diab Nutr Metab*; 14: 140-152, 2001.
86. Annunzi G.,Del Prato S.,Arcari R.,Bellomo Damato A.,Benzi L.,Bruttomesso D., Calderini MC,.Costelli C,.Fedele D,.Galluzzo A,.Giordano M,.Giorgino R,.Lapolla A,.Orsini P,.Pagano G,.Santoro D,. Riccardi G. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. *Nutr Metab Cardiovasc Dis*, 11: 168-175, 2001.
87. . Serrano-Rios M, Melchionda N., Moreno-Carretero E Role of sibutramine in the treatment of obese type 2 diabetic patients receivimg sulphonylurea therapy. *Diabetic Medicine* 19,119-24, 2002.
88. Gualdiero P, Esposito K, Ciotola M, Marfella R, Giugliano D. Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. *J Endocrinol Invest*. 25(6):RC16-8, 2002.
89. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. *Diabetes Metab Res Rev*. 18(2):114-7, 2002.
90. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. *Eur J Heart Fail*.5(6):803-9, 2003.

- 91.** Pozzilli P, Crinò A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, Pitocco D, Visalli N, Corbi S, Spera S, Suraci C, Cervoni M, Matteoli MC, Patera IP, Ghirlanda G; IMDIAB Group. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). *Diabetes Technol Ther.* 5(6):965-74, 2003.
- 92.** Mosca A., Paleari R.A, Ceriotti F., Lapolla A., Fedele D for the Lecarnidipine Study Group. Biological variability of albumin excretion rate and albumin-to-creatinine ratio in hypertensive type 2 diabetic patients. *Clin Chem Lab Med* 41(9):1229-33, 2003.
- 93.** Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. *Diabetes Care.*;26(5):1490-6, 2003.
- 94.** Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. *Diabet Med.* 21(11):1213-20, 2004.
- 95.** Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. *Clin Ther.* 4:502-10. 2004.
- 96.** Consoli A, Gomis R, Salimi S, Home PD, Mehnert H, Strojek K, van Gaal LF: Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. *Diabetes Metab*, 30: 509-516, 2004.
- 97.** Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA.* 292(12):1440-6, 2004.
- 98.** Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lecarnidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria. DIAL Study (Diabete, Ipertensione, Albuminuria, Lecarnidipina). *Diab Nutr Metab* 17(5): 259-266, 2004.

- 99.** Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P; IMDIAB group. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). *Eur J Endocrinol.* 150(5):719-24, 2004.
- 100.** Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. *Diabetes Res Clin Pract.* 68:S22-S29, 2005.
- 101.** Laviola, L., Cignarelli A, Giorgino F.. Clinical view on the need to develop new anti-diabetic drugs. *Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents* 5:469-474, 2005.
- 102.** Veneri D., Franchini M., Bonora E. Regression of type 2 diabetes with imatinib? *N. Engl. J. Med.* 352: 1049-1050, 2005 .
- 103.** Crinò A, Schiaffini R, Ciampalini P, Suraci MC, Manfrini S, Visalli N, Matteoli MC, Patera P, Buzzetti R, Guglielmi C, Spera S, Costanza F, Fioriti E, Pitocco D, Pozzilli P; IMDIAB Group. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. *J Pediatr Endocrinol Metab.* 18(8):749-54, 2005.
- 104.** Restivo D.A., Marchese-Ragona R., Lauria G., Squatrito S., Gullo D., Vigneri R. Botulinum Toxin Treatment or Oropharyngeal Dysphagia Associated With Diabetic Neuropathy. *Diabetes Care* 29: 2650-2653, 2006.
- 105.** Pozzilli P, Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. *Ann N Y Acad Sci.* 1079:90-8, 2006.
- 106.** Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). *Diabet Med.* 23(8):920-3, 2006.
- 107.** Kautzky-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. *Diabetes Obes Metab.* 8(5):561-7, 2006.
- 108.** Federici MO, Mosca A, Testa R, Lapolla A, Andreani P, Benedetti MM, National survey on the execution of the oral glucose tolerance test (OGTT) in a representative cohort of Italian laboratories. *Clin Chem Lab Med.* 44:567-573, 2006.

- 109.** Giorgino, F., L. Laviola, A. Natalicchio, A., Leonardini. GLP-1: a new approach for type 2 diabetes therapy. *Diabetes Research and Clinical Practice* 74S2:S152-155, 2006.
- 110.** Giorgino, F., Natalicchio A., Leonardini A, Laviola L.. Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. *Diabetes Research and Clinical Practice* 78S:S59–S67, 2007.
- 111.** Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. *Int. J. Clin. Pract.* 154, suppl: 19-28, 2007.
- 112.** Lighthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in Clinical Practice *Clinical Therapeutics* 29: 1284-1292, 2007.
- 113.** Pozzilli P. Immuno-intervention and preservation of beta-cell function in type 1 diabetes. *Diabetes Metab Res Rev.* 23(4):255-6, 2007.
- 114.** Porcellati F, Rossetti P, Ricci NB, Panpanelli S, Torlone E, Campos SH, Andreoli AM, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. *Diabetes Care* 30(5):1261, 2007.
- 115.** Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P.: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 9:186-193, 2007.
- 116.** Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P.: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to on-going metformin on 24-hour glycemic control and Beta-cell function in patients with type 2 diabetes. *Diabetes Obesity and Metabolism* 9:186-193, 2007.
- 117.** Basu R., Dalla Man C., Campioni M., Basu A., Nair K S., Jensen M.D., Khosla S., Klee. G., Toffolo G., Cobelli C., Rizza R.A.: Two years of treatment with dehydroepiandrosterone does not improve insulin secretion action or postprandial glucose turnover in elderly men or women. *Diabetes* 56:753-66, 2007.
- 118.** Del Prato S, Bianchi C, Miccoli R, Penno G. Pharmacological intervention in prediabetes: considering the risks and benefits. *Diabetes Obes Metab;* 9 Suppl 1: 17-22., 2007.

- 119.** Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. *Horm Metab Res*. 39(11):826-9, 2007.
- 120.** Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. *Arch Physiol Biochem*. 114(1):3-10, 2008.
- 121.** Marfella R, Barbieri M, Paolisso G. Insulin therapy and lipid overload in type 2 diabetes. *JAMA*. 300(7):789, 2008.
- 122.** Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. *Diabet Med*. 25(11):1259-67, 2008.
- 123.** Ravikumar B., Gerrard J., Dalla Man C., Firbank M.J., Lane A., English P.T., Cobelli C., Taylor R.: Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. *Diabetes* 57:2288-95, 2008.
- 124.** Xu L., Dalla Man C., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., Cobelli C., Stein P.P.: Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. *Diabetes Obes. Metab*. 10:1212-20, 2008.
- 125.** Azuma K., Rádiková Z., Mancino J., Toledo F.G., Thomas E., Kangani C., Dalla Man C., Cobelli C., Holst J.J., Deacon C.F., He Y., Ligueros-Saylan M., Serra D., Foley J.E. Kelley D.E. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab*. 93:459-64, 2008.
- 126.** Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. *Diabetes Care*. 31(10):1966-71, 2008.
- 127.** Pitocco D, DiStasio E, Crinò A, Manfrini S, Guglielmi C, Visalli N, Suraci C, Matteoli MC, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group. Age at diagnosis of type 1 diabetes and the effect of immunomodulatory therapies on residual beta cell function. *Horm Metab Res*. 40(1):66-8, 2008.
- 128.** Chianelli M, Parisella MG, Visalli N, Mather SJ, D'Alessandria C, Pozzilli P, Signore A; IMDIAB study group. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of

- type 1 diabetes and after 1 year of nicotinamide therapy. *Diabetes Metab Res Rev.* 24(2):115-22, 2008.
- 129.** Bianchi C, Penno G, Daniele G, Benzi L, Del Prato S, Miccoli R. Optimizing management of metabolic syndrome to reduce risk: focus on life-style. *Intern Emerg Med.*; 3: 87-98, 2008.
- 130.** Bossi AC, Ansah EO. Bent needles: another problem in glycaemic control. *Diabetes Care* 31(10):e70, 2008.
- 131.** Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, Rabuazzo AM, Piro S, Alagona C, Spadaro L, Purrello F, Pezzino V. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. *Acta Diabetol* 45:53-59, 2008.
- 132.** Imbergamo, M.P., Amato, M.C., Sciortino, G., Gambina, M., Accidenti, M., Criscimanna, A., Giordano, C., Galluzzo, A Use of glargin in pregnant women with Type 1 diabetes mellitus: A case-control study. *Clinical Therapeutics* 30 (8):1476-1484, 2008.
- 133.** Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). *Clin Endocrinol (Oxf)*. 69(6):963-9, 2008.
- 134.** Valensi P, Benrouri M, Borzì V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M Wenying Y. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. *International Journal of Clinical Practice*; 62;1809-1819, 2008.
- 135.** Shah S, Benrouri M, Borzì V, Gumprecht J, Kawamori R, Shaban J, Shestakova M Wenying Y Valensi P. Safety and effectiveness of biphasic insulin aspart 30/70(NovoMix30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study *International Journal of Clinical Practice*; 63: 574-582, 2009.
- 136.** Marfella R, Portoghesi M, Ferraraccio F, Siniscalchi M, Babieri M, Di Filippo C, D'Amico M, Rossi F, Paolisso G. Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function. *Heart*. 95(12):1020-2, 2009.
- 137.** Dalla Man C., Bock G., Giesler P.D., Serra D.B., Ligueros Saylan M., Foley J.E., Camilleri M., Toffolo G., Cobelli C., Rizza R.A, Vella A.: Dipeptidyl peptidase 4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. *Diabetes Care* 32:14-8, 2009.

- 138.** Valensi P, Benroubi M, , Borzì V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M Wenying Y. Initiating insulin therapy with, or switching existing insulin therapy to biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study International Journal of Clinical Practice 63: 522-531, 2009.
- 139.** Gumprecht J, Benroubi M, Borzì V, Kawamori R, Shaban J, Shah S, Shestakova M Wenying Y, Lighthelm RJ, Valensi P. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study Int J Clin Pract.; 63:966-972, 2009.
- 140.** Wenying Y, Benroubi M, Borzì V, Gumprecht J Kawamori R, Shaban J, Shah S, Shestakova M, Lighthelm RJ, Valensi P Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study Current Medical Research Opinion 25(11): 2643-2654, 2009.
- 141.** Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care.; 32 Suppl 2: S217-22, 2009.
- 142.** Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care.; 32 Suppl 2: S342-8, 2009.
- 143.** Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis. 19(8):571-9, 2009.
- 144.** Mannarino E, Pirro M., Cortese C., Lupattelli G., Siepi D., Mezzetti A, Bertolini S., Parillo M, Fellin R., Pujia A., Averna M., Nicolle C., Notarbartolo A. Effects of a phytosterol-enriched dairy product on lipids, sterols, and 8-isoprostanate in hypercholesterolemic patients: A multicenter Italian study. Nutrition, Metabolism and Cardiovascular Diseases 19, 84-90, 2009.
- 145.** Iannuzzi A., Licenziati MR., Vacca M., De Marco D, Cinquegrana G., Laccetti M, Bresciani A., Covetti G., Iannuzzo G, Rubba P., Parillo M: Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. Heart Vessels 24(6):419-424, 2009.

- 146.** Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). *Horm Metab Res.* 41(7):573-9, 2009.
- 147.** Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. *Nutr. Metab. Cardiovasc. Dis.* 19(1):45-53, 2009.
- 148.** Cernea S, Buzzetti R, Pozzilli P. Beta-cell protection and therapy for latent autoimmune diabetes in adults. *Diabetes Care.* 32 Suppl 2:S246-52, 2009.
- 149.** Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP; D-Cure Workshop Challenges in developing endpoints for type 1 diabetes intervention studies. *Diabetes Metab Res Rev.* 25(8):694-704, 2009.
- 150.** Pozzilli P, Leslie RD. New prospects for immunotherapy at diagnosis of type 1 diabetes. *Diabetes Metab Res Rev.* 25(4):299-301, 2009.
- 151.** Khoo CP, Valorani MG, Brittan M, Alison MR, Warnes G, Johansson U, Hawa M, Pozzilli P Characterization of endothelial progenitor cells in the NOD mouse as a source for cell therapies. *Diabetes Metab Res Rev.* 25(1):89-93, 2009.
- 152.** Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). *The Lancet* 374, 39-47, 2009.
- 153.** Sesti G. Harnessing the weight-regulating properties of GLP-1 in the treatment of type 2 diabetes. *Diabetes Obes Metab.* 11 (Suppl. 3): 4-10, 2009.
- 154.** Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. *Clin Ther* 31:2472-2488, 2009.
- 155.** Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; for the Liraglutide Effect and Action in Diabetes (LEAD)-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. *Diabetes Care* 33:1300-1303, 2010.
- 156.** Balasubramanian R., Gerrard J., Dalla Man C., Firbank M.J., Lane A., English P.T., Cobelli C., Taylor R.: Combination peroxisome proliferator-activated receptor gamma and

- alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content. *Diabetic Medicine* 27:150-156, 2010.
- 157.** Bock G., Dalla Man C., Micheletto F., Basu R., Giesler P.D., Laugen J., Deacon C.F., Holst J.J., Toffolo G., Cobelli C., Rizza R.A., Vella A.: The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. *Clinical Endocrinology* 73: 189-196, 2010.
- 158.** Fadini GP, Albiero M, Menegazzo L, Boscaro E, Pagnin E, Iori E, Cosma C, Lapolla A, Pengo V, Stendardo M, Agostini C, Pelicci P, Giorgio M, Avogaro A. The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. *Diabetes* 59 (9): 2306-14, 2010 .
- 159.** Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Perna A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, and Remuzzi G for the Ezetimibe and Simvastatin in dyslipidemia of Diabetes (ESD) Study Group. Effects of combined Ezetimibe and Simvastatin Therapy as compared to Simvastatin alone in Patients with Type 2 Diabetes: a Prospective, Randomized, Double-Blind, Clinical Trial. *Diabetes Care* 33:1954-1956, 2010.
- 160.** Pratley RE, Nauck M, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open trial *Lancet* 375: 1447-1456, 2010.
- 161.** Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). *Cardiovasc Diabetol*. 21; 9: 20, 2010.
- 162.** Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. *Am J Cardiol*. 106(9):1292-6, 2010.
- 163.** Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. *Drugs*.70(1):41-56, 2010.
- 164.** Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. *Diabetologia* 53:1743-53, 2010.
- 165.** Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. *Acta Diabetol*. 47:271-78, 2010.

- 166.** Marfella R, Luongo C, Coppola A, Luongo M, Capodanno P, Ruggiero R, Mascolo L, Ambrosino I, Sardu C, Boccardi V, Lettieri B, Paolisso G. Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. *Atherosclerosis*. 208(2):473-9, 2010.
- 167.** Fatati G, Cortinovis F, Fontana L, Fusco MA, Leotta S, Marelli G, Mirri E, Parillo M.; Sukkar SG, Tagliaferri M, Tomasi F, Tubili C. ADI-AMD recommendations on insulin treatment during artificial nutrition. *Mediterr J Nutr Metab.* 3 1-8, 2010.
- 168.** Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG, Guazzini B, Testori G, Fogari E, Maffioli P. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. *Eur J Pharmacol* 666(1-3):251-6, 2011.
- 169.** Marfella R, Paolisso G. Reply to the "Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'", by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353). *J Diabetes Complications.* 25(6):405-6, 2011.
- 170.** Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. *Diabetes Care.* 34 Suppl 2: S231-S235, 2011.
- 171.** Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. *J Endocrinol Invest.*; 34:69-77, 2011.
- 172.** Bellomo Damato A, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. *Diabet Med.*; 28:560-566, 2011.
- 173.** Busetto L, Sbraccia P, Frittitta L, Pontiroli AE. The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions. *Obes Surg.* 21(9):1451-7, 2011.
- 174.** Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. *Diabetes Obes Metab.* 13(12):1149-57, 2011.
- 175.** Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. *Diabetes Obes Metab.* 13(11):1008-19, 2011.
- 176.** Sesti G. Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists. *Diabetes Care* 34 (Suppl. 2), S272-275, 2011.

- 177.** Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. *Endocr Pract* 17: 906-13, 2011.
- 178.** Pozzilli P. Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. *Nat Rev Endocrinol.* 20;8(2):78-80, 2011.
- 179.** Pozzilli P, Guglielmi C, Maggi D, Carbone A, Buzzetti R, Manfrini S. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes. *Curr Pharm Des.* 17(29):3224-8, 2011.
- 180.** Tuccinardi D, Fioriti E, Manfrini S, D'Amico E, Pozzilli P. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes. *Expert Opin Biol Ther.* 11(9):1233-40, 2011.
- 181.** Metra M, Bettari L, Carubelli V, Bugatti S, Dei Cas A, Del Magro F, Lazzarini V, Lombardi C, Dei Cas L. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. *Drugs.* 71(5):515-25, 2011.
- 182.** Nesso G, Angrisani L, Saldalamacchia G, Cutolo PP, Cotugno M, Lupoli R, Vitolo G, Capaldo B. Impact of sleeve gastrectomy on weight loss, glucose homeostasis, and comorbidities in severely obese type 2 diabetic subjects. *J Obes.* 2011:340867, 2011.
- 183.** Bonfante L, Virga G, Lapolla A, Toffolo K, Del Prete D, Scaparrota G, Alessi M, D'Angelo A. Suspension of ACE-I and ARB Treatment Is Associated with Acute Increase in Serum AGE Levels in Patients on Peritoneal Dialysis. *Perit Dial Int.* 31(1):94-7, 2011.
- 184.** Orioli M, Vistoli G, Regazzoni L, Pedretti A, Lapolla A, Rossoni G, Canevotti R, Gamberoni L, Previtali M, Carini M, Aldini G. Design, Synthesis, ADME Properties, and Pharmacological Activities of β -Alanyl-D-histidine (D-Carnosine) Prodrugs with Improved Bioavailability. *ChemMedChem.* 6(7): 1279-82, 2011.
- 185.** Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. *Expert Opin Pharmacother.* 12(16):2449-55, 2011. *Erratum in: Expert Opin Pharmacother. 2011 Dec;12(17):2765.*
- 186.** Bruno G, De Micheli A, Frontoni S, Monge L; Società Italiana di Diabetologia-Associazione Medici Diabetologi (SID-AMD) Working Group on the Standards of Care for Diabetes. Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". *Nutr Metab Cardiovasc Dis.* 21:302-14, 2011.

- 187.** Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. *Diabetes Care* 34(12):2524-6, 2011.
- 188.** Irace C, Fiorentino R, Carallo C, Scavelli F, Gnasso A. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. *Diabetes Technol Ther* 13:1261-1263, 2011.
- 189.** Parillo M, Annuzzi G., Rivelles A. A., Bozzetto L., Alessandrini R., Riccardi G: Effects of meals with different glycaem index on postprandial blood glucose response in patients with Type 1 diabetes treated with continuous subcutaneous insulin infusion *Diabetic Medicine*. 227 – 229, 2011.
- 190.** Consoli A. New therapeutic algorithm of Type 2 diabetes: Lights and shadows. *J Endocrinol Invest*. 34(1):65-8, 2011.
- 191.** Pozzilli P, Strollo R. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression. *Immunotherapy*. 4(7):655-8, 2012.
- 192.** Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? *Adv Ther*. 29(3):218-33, 2012.
- 193.** Roth J, Pozzilli P. Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". *Diabetes Metab Res Rev* 2012. *Diabetes Metab Res Rev*. 28(4):325, 2012.
- 194.** Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition. *Diabetes Care*. 35(10):2076-82, 2012.
- 195.** Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, Carbonara O, Gualdiero P, Petronella P, Ferraraccio F, Petrella A, Canonico R, Campitiello F, Della Corte A, Paolisso G, Canonico S. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. *Exp Diabetes Res*. 2012:892706, 2012.
- 196.** Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Åman J, Kärdell G, Neiderud Helsingborg J, Lundström G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanås R, Larsson K, Rathsmann B, Forsgren H, Desaix H, Forsander G, Nilsson NÖ, Åkesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A,

- Rica I, Barrio R, Clemente M, López Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. *N Engl J Med.* 2;366(5):433-42, 2012.
- 197.** Parillo M., Licenziati MR, Vacca M, DeMarco D, Annuzzi A. Metabolic Changes after Hypocaloric, Low Glycemic Index diet in obese children. *J Endoc Investigation* 35,629-33, 2012.
- 198.** Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. *Diabetes Obes Metab.* 14(5):433-46, 2012.
- 199.** Palermo, Maddaloni E., Pozzilli P, Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence? *Expert Opinion on Biological Therapy*, vol. 12, no. 6, pp. 767–72, 2012.
- 200.** Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol.* 49:193-197, 2012.
- 201.** Bolli GB, Consoli A, Giaccari A. Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results. *Nutr Metab Cardiovasc Dis.* 22(12):1007-12, 2012.
- 202.** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364-1379. *Diabetes Care.* 35:e71, 2012.
- 203.** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Evaluation of guidelines on diabetes medication. *Ann Intern Med.*,156:752-3, 2012.
- 204.** Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. NN1250-3582 (BEGIN BB T2D) Trial Investigators. *Lancet* 21; 379(9825):1498-507, 2012.

- 205.** Vaccaro O., Masulli M., Bonora E., Del Prato S., Nicolucci A., Rivelles A.A., Riccardi G. on behalf of the TOSCA.IT Study Group. The TOSCA.IT Trial: A study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. *Diabetes Care* 35:e82, 2012.
- 206.** Vaccaro O., Masulli M., Bonora E., Del Prato S., Giorda C.B., Maggioni A.P., Mocarelli P., Nicolucci A., Rivelles A.A., Squatrito S., Riccardi G.; on behalf of the TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. *Nutr. Metab. Cardiovasc. Dis.* 22: 997-1006, 2012.
- 207.** Borzì V Benroubi M, , Gumprecht J Kawamori R Lighthelm RJ, Shaban J, Shah S, Shestakova M, , Wenying Y Valensi P Predictors of postprandial blood glucose response to biphasic insulin analogue therapy *Prim. Care Diab.*; 7; 63- 67, 2012.
- 208.** Giorda CB, Mulas MF, Manicardi V, Suraci C, Guida P, Marafetti L, Nada E, Gentile S Factors associated with a rapid normalization of HbA1c in newly diagnosed type 2 diabetes patients seen in a specialist setting. *Acta Diabetologica* 09, 2012.
- 209.** DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group (Orsi E). Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. *Diabetes Care*. 35:1446-1454, 2012.
- 210.** Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V Shah S Wenying Y, Prusty V, Hansen JB Gumprecht J Predictors of achieving HbA_{1c} <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study *Current Medical Research and Opinion*,; 29: 601-609, 2013.
- 211.** Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. *Atherosclerosis*. 227(2):349-54, 2013.
- 212.** Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research. *Diab Vasc Dis Res* 10:72-77, 2013.
- 213.** Boccardi V, Barbieri M, Rizzo MR, Marfella R, Esposito A, Marano L, Paolisso G. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. *FASEB J.* 27(9):3879-85, 2013.

- 214.** Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. *Diabetes Metab Syndr Obes*; 6: 161-170, 2013.
- 215.** Opinto G, Natalicchio A, Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. *Arch Physiol Biochem*; 119: 170-8, 2013.
- 216.** Maggi S, Noale M, Pilotto A, Tiengo A, Cavallo Perin P, Crepaldi G; Metabolic Working Group. The METABOLIC Study: multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. *Diabetes Metab*; 39:236-243, 2013.
- 217.** Consoli A, Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? *Diabetes Obes Metab*. 15(11):967-77, 2013.
- 218.** Beltramello G, Manicardi V, Trevisan R Trialogue : Managing hyperglycaemia in internal medicine: instructions for use. *Acta Diabetologica* 04, 2013.
- 219.** Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, Morano S, Ferrannini E, Pugliese G; Renal Insufficiency and Cardiovascular Events Study Group. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events italian multicenter study. *J. Am. Geriatr. Soc*. 61:1253-1261, 2013.
- 220.** Micheletto F., Dalla Man C., Kolterman O., Chiquette E., Herrmann K., Schirra J., Kovatchev B., Cobelli C.: In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. *Diabetes Technol Ther*. 15: 802- 809, 2013.
- 221.** King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1c targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1c <8.0%. *Endocr Pract* 19: 64-72, 2013.
- 222.** Ohlsson L, Alsalm W, Carr RD, Tura A, Pacini G, Mari A, Ahrén B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. *Diabetes Obes Metab*. 15(6):531-7, 2013.
- 223.** Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D; PRISMA study group, Egan CG, Chinea B, Bravi F, Di Pietro C. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. *J Endocrinol Invest*. 36(8):606-16, 2013.
- 224.** Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL. Exenatide promotes cognitive enhancement and positive

- brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. *Cell Death Dis.* 4:e612, 2013.
225. Dardano A, Penno G, Del Prato S, Miccoli R. Optimal therapy of type 2 diabetes: a controversial challenge. *Aging (Albany NY)*. 6: 187-206, 2014.
226. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R. NIRAD Study Group. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*. 171(6):697-704, 2014.
227. Khazrai Y. M., Maddaloni E, Altomare M., Caciapaglia F, Pozzilli P New technologies aiding dietary programmes for weight control: the oral glucose spray.,” *Endocrine*, vol. 45, no. 2, pp. 288-292, 2014.
228. Maddaloni E., Pozzilli P., Comment on: “Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. *Nutrition Metabolism and Cardiovascular Disease*, vol. 24, no. 1, p. e1, 2014.
229. Maddaloni E., Pozzilli P., SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes)". *Endocrine*, vol. 46, no. 1, pp 3-5, 2014.
230. Rizzo M, Chandalia M, Patti A, Di Bartolo V, Rizvi AA, Montaldo G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. *Cardiovasc Diabetol* 13:49, 2014.
231. Brunetti A, Brunetti FS, Chieffari E. Pharmacogenetics of type 2 diabetes mellitus: An example of success in clinical and translational medicine. *World J Transl Med*. 3: 141-149, 2014.
232. Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). *Am J Cardiol*. 114(5):743-50, 2014.
233. Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. *Diabetologia*. 57(6):1199-203, 2014.
234. Van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, Smith U, Diamant M. The effect of alogliptin and

- pioglitazone combination therapy on various aspects of β -cell function in patients with recent-onset type 2 diabetes. *Eur J Endocrinol.* 8;170(4):565-74, 2014.
235. Brunetti A. Individualizing Care in Type 2 Diabetes Mellitus. *J Diabetes Metab Disord Control* 1: 00020, 2014
236. Muscogiuri G, Cignarelli A, Giorgino F, Prodram F, Santi D, Tirabassi G, Balercia G, Modica R, Faggiano A, Colao A. GLP-1: benefits beyond pancreas. *J Endocrinol Invest.* . 38:115, 2015.
237. Lindgren O, Pacini G, Tura A, Holst JJ, Deacon CF, Ahrén B. Incretin Effect after Oral Amino Acid Ingestion in Humans. *J Clin Endocrinol Metab.* 100:1172-6, 2015.
238. Lapolla A, Frison V, Bettio M, DalPos M, Ronchini P, Panebianco G, Tadiotto F, DaTos V, D'Ambrosio M, Marangoni A, Ferrari M, Pianta A, Balzano S, Confortin L, Lamonica M, Marin N, Strazzabosco M, Brun E, Mesturino CA, Simoncini M, Zen F, Bax G, Bonsembiante B, Cardone C, Dalfrà MG, Gallo A, Masin M, Piarulli F, Sartore G, Simioni N. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-wordl setting. *Clin Ther* S0149-2918(14)00829-7 , 2015.
239. Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. *Expert Opin Drug Saf.*, 14:207-218, 2015.
240. Ampudia-Blasco FJ, Benhamou PY, Charpentier G, Consoli A, Diamant M, Gallwitz B, Khunti K, Mathieu C, Ridderstråle M, Seufert J, Tack C, Vilsbøll T, Phan TM, Stoevelaar H. A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. *Diabetes Technol Ther.* 17:194-202, 2015.
241. Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffi E, Lupoli R, Angrisani L, Riccardi G, Capaldo B. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. *Acta Diabetol.* 52:331-6 , 2015.
242. Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, Marino AG, Barbagallo I, Isenovic ER, Banach M, Montalto G, Volti GL. Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 And Ghrelin Levels In Patients With Type 2 Diabetes: a prospective pilot study. *J Clin Endocrinol Metab.* 100:603-6, 2015.